Drug Interactions between celecoxib / tramadol and sofpironium topical

Celecoxib may increase the blood levels and effects of traMADol. If your doctor does prescribe these medications together, you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if you experience increased side effects or if your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.

MANAGEMENT: Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2-fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose. Clinical data for sofpironium use in combination with other less potent CYP450 2D6 inhibitors are not available.

MANAGEMENT: Caution is advised when sofpironium topical is used concurrently with CYP450 2D6 inhibitors. Patients should be more closely monitored for adverse effects such as blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.